Both are heralded as a new first-line standard of care, but Datroway seems to have the edge.

Enhertu improves outcomes in (neo)adjuvant breast cancer, but toxicity resurfaces.

Keynote-905 finds a 50% reduction in the risk of death in (neo)adjuvant muscle-invasive bladder cancer.

First data with Astra’s torvutatug samrotecan come as Lilly unveils its first folate pivotal trial.

Data with the T-cell engager ASP2138 look lukewarm, but could improve with combos.

And Vironexis’s second gene therapy-encoded T-cell engager will soon go clinical.

And Treeline and HengRui also get in on the pan-RAS act.

Datroway succeeds on PFS and OS in Tropion-Breast02, and an ESMO showdown beckons.